Astrazeneca Pharma India Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8369 as of 06 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 0 on June 2024 . This represents a CAGR of -100.00% over 9 yearsThe P/E Ratio of Procter & Gamble Health Ltd changed from 27.3 on March 2025 to 41.7 on June 2024 . This represents a CAGR of 8.84% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 0 crore on June 2024 . This represents a CAGR of -100.00% over 9 yearsThe Market Cap of Procter & Gamble Health Ltd changed from ₹ 8535 crore on March 2025 to ₹ 8382 crore on June 2024 . This represents a CAGR of -0.36% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 496.63 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the decline of -12.14% The revenue of Procter & Gamble Health Ltd for the Mar '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 329.87 crore. This represent the decline of -100% The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 96.84 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the growth of 27.32% The ebitda of Procter & Gamble Health Ltd for the Mar '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 125.22 crore. This represent the decline of -100% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 58.25 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Procter & Gamble Health Ltd changed from ₹ 82.33 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 0 % on June 2024 . This represents a CAGR of -100.00% over 9 yearsThe Dividend Payout of Procter & Gamble Health Ltd changed from 88.52 % on March 2025 to 214.75 % on June 2024 . This represents a CAGR of 19.39% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Procter & Gamble Health Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,923 Cr while Market cap of Procter & Gamble Health Ltd is 8,854 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Procter & Gamble Health Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Procter & Gamble Health Ltd?

As of May 6, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8369.45. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5334.05.

How do dividend payouts of Astrazeneca Pharma India Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.